WO2000051562A1 - Inhibiteur des metalloproteases matricielles et utilisation associee - Google Patents

Inhibiteur des metalloproteases matricielles et utilisation associee Download PDF

Info

Publication number
WO2000051562A1
WO2000051562A1 PCT/JP2000/001260 JP0001260W WO0051562A1 WO 2000051562 A1 WO2000051562 A1 WO 2000051562A1 JP 0001260 W JP0001260 W JP 0001260W WO 0051562 A1 WO0051562 A1 WO 0051562A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
skin
mmp
plant
activity
Prior art date
Application number
PCT/JP2000/001260
Other languages
English (en)
Japanese (ja)
Inventor
Shinji Inomata
Yumiko Suzuki
Kenichi Umishio
Tomomi Okazaki
Masahiro Ota
Original Assignee
Shiseido Company, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP05494999A external-priority patent/JP3632951B2/ja
Priority claimed from JP32074799A external-priority patent/JP2001139466A/ja
Priority claimed from JP2000005704A external-priority patent/JP2001192316A/ja
Application filed by Shiseido Company, Ltd. filed Critical Shiseido Company, Ltd.
Publication of WO2000051562A1 publication Critical patent/WO2000051562A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Definitions

  • the present invention relates to the technical fields of cosmetics and dermatology, and more specifically, to cosmetic and dermatological extracts of medicinal plants or their components that inhibit human matrix metalloproteinase (MMP) activity. For use in the scientific field.
  • MMP matrix metalloproteinase
  • the epidermis and dermis are in contact through the basement membrane.
  • the basal cells In the basement membrane, the basal cells repeatedly divide and intolerate, and the divided basal cells are sequentially pushed upward to form the stratum corneum, the uppermost layer of the epidermis. Since the stratum corneum is very closely related to the cosmetic properties of the skin, the physiological or morphological properties of the basement membrane also have a significant effect on the skin.
  • the basement membrane is a type of extracellular matrix and contains type IV collagen, proteoglycan, laminin, fibronectin, and the like.
  • Extracellular matrix consists of fibrous proteins (collagen, elastin, etc.) and cell adhesion proteins (glycosaminoglycan, proteoglycan, fibronectin, laminin, etc.).
  • fibrous proteins collagen, elastin, etc.
  • cell adhesion proteins glycosaminoglycan, proteoglycan, fibronectin, laminin, etc.
  • the physiological or morphological properties of the Rix are considered to have a significant effect on the elasticity, firmness, etc. of the skin.
  • any of the active ingredients described is mainly active in activating the skin, in particular, a skin care effect on damaged skin.
  • MMPs matrix metalloproteases
  • the group of gelatinases includes MMP-2, MMP-19 and so on. These MMP-2 and 9 are known as enzymes that degrade basement membrane components such as type IV collagen and laminin, and dermal matrix component elastin.
  • the stromelysin group includes MMP-3, MMP-10, etc. These MMP_3 and MMP_10 are known as enzymes that degrade proteoglycan, a basement membrane component, type IV collagen, laminin, and other fibronectin.
  • each of these enzymes is greatly increased by irradiation with ultraviolet light, which is one of the causes of decomposing and denaturing extracellular matrix caused by ultraviolet light, and is one of the major factors such as the formation of skin wrinkles (Gary J. Fisher et al., “Nature”, 379 (25), 335 (1996); Gary J. Fisher et al., “The New England Journal of Medicine", 337 (20), 1 419 (1997)).
  • ultraviolet light is one of the causes of decomposing and denaturing extracellular matrix caused by ultraviolet light
  • TIMP tissue inhibitor of metalloprotease
  • the present inventors have now found that an extract or a component thereof derived from a wide variety of medicinal plants inhibits MMPs activity and, in fact, can prevent human skin aging.
  • the present invention is based on such findings.
  • the present invention provides, as an active ingredient, an extract derived from a medicinal plant that inhibits the activity of Matrix Meta-Mouth Proteaase (MMP) in human or an ingredient thereof, and other ingredients used in the composition for external use on skin And a composition for external use on the skin for preventing or improving skin aging.
  • MMP Matrix Meta-Mouth Proteaase
  • the present invention provides an extract or extract derived from a medicinal plant that inhibits the activity of human matrix protease (MMP) in a method for preparing an external skin composition for preventing or improving skin aging. Regarding the use of that ingredient.
  • MMP human matrix protease
  • the present invention provides a human skin in need of prevention or amelioration of skin aging, which has sufficient human matrix meta-oral protease (MMP) activity required for the prevention or amelioration.
  • An extract derived from a medicinal plant that inhibits or a component thereof is transdermally administered, and selected from the group consisting of type I and III collagen, type IV collagen, laminin, and proteoglitin that constitute the extracellular matrix in the skin Skin aging comprising a step of preventing the degradation or degeneration of at least one protein It also relates to prevention or improvement measures.
  • an extracellular matrix component eg, elastin, laminin, proteoglycan, basement membrane
  • an extracellular matrix component eg, elastin, laminin, proteoglycan, basement membrane
  • the term "medicinal plant” as used in the present invention includes preparations, dried products, extracts, essential oils, and crude or highly purified substances derived therefrom, for example, described as pharmaceuticals in the Japanese Pharmacopoeia. Or a plant that has been passed down by the private sector for use as a crude drug, or to prevent or treat any disease, as long as it meets the purpose of the present invention. Any plants are included.
  • a preferred plant is a medicinal plant-derived extract or a component thereof, which is lower than ethylenediaminetetraacetic acid (EDTA), which is known to have an MMPs inhibitory action. Plants which significantly inhibit MMP activity in the in vitro MMP activity measurement system described below at a concentration of, for example, 0.001 to 0.005% by weight can be mentioned.
  • MMP activity to be inhibited examples include at least one selected from the group consisting of gelatinase activity, stromelysin activity and collagenase activity.
  • gelatinase is selected from MMP-9 (Or gelatin B)
  • stromelysin is MMP-3 (or stromelysin 1)
  • collagenase is MMP-1 It is contemplated.
  • the medicinal plants include, but are not limited to, the following plants: Thymus serpyllum L., Tachija kohyoso "hymus Vulagris L.”, and Origanum ma joran a. L.) selected from the group consisting of Labiatae plants and their relatives; Zingiberaceae (Zingiberaceae) such as the genus (Curcuma) belonging to the genus Curcuma (CCurcuma longa L.) and the currant (Curcuma xanthorrhiza Roxb.) ) Plants and their relatives; Potentilla tormentilla Schrk Cr Crataegus cuneate Siebold et Zuccarini) or ⁇ Remoco ⁇ (Sanguisorba officinalis Linne) Rosaceae plants, and their relatives; Ti lia cordata Mill.
  • Sinensis DC. Walnut (Juglndaceae) plant, and its related line.
  • the above-mentioned closely related line refers to a variant or mutant line in which a slight difference in phenotype or genotype is observed depending on the place of origin or cultivation place. Whether or not the varieties or mutant lines of each of the above plants are within the scope of the present invention can be determined based on whether or not they have the inhibitory effect on MMP activity as described above.
  • extracts or their components from medicinal plants as described above can be obtained as they are from commercially available crude drugs or by subjecting commercially available crude drugs to simple purification, extraction, etc. it can. If the extract or its components are not commercially available, obtain the plant parts used by the corresponding plant (for example, whole plants, rhizomes, leaves, etc.) and soak or heat to reflux with the extraction solvent. After that, it can be obtained by filtration and concentration.
  • the extraction solvent any solvent can be used as long as it is a solvent usually used for extraction.
  • water for example, water, alcohols such as methanol, ethanol, propylene glycol, 1,3-butylene glycol and glycerin, and hydrous alcohols And organic solvents such as chloroform, dichloroethane, carbon tetrachloride, acetone, ethyl acetate, hexane and the like can be used alone or in combination.
  • Extract solution obtained by extraction with the above solvent The concentrated extract is adsorbed on a column of a porous polymer (for example, Amberlite XAD-2), and then eluted with methanol or ethanol. Concentrated ones can also be used.
  • a partitioning method for example, an extract extracted with water Z ethyl acetate is also used.
  • a plant part or a treatment method that is convenient for obtaining the extract or its component used in the present invention can be performed, for example, by referring to the Hirokawa Medicinal Plant Encyclopedia, Tokyo Hirokawa Publishing Co., 1980. See Issue 25.
  • the components of the extract are: ⁇ Substances that can be obtained from the extract using the inhibitory activity of the activity as an index through further isolation / purification methods including the column method and the partition method described above (mixture of multiple active ingredients) Or it can be a specific compound.
  • particularly preferred components include, for example, curcumin, which can be obtained from rhizomes of radish (Curcuma longa L.):
  • Curcumin C 21 H 20 O 6
  • Curcumin has antioxidant and anticancer effects (Toshihiko Osawa, "Fragrance J.”, 1993, 11, .70; Khar A. eta 1., "FEBS Lett.”, 445 (1), 165 (1999) )) Is known, and it is also used in Chinese medicine as a hemostatic and stomachic.
  • Curcumin is an isomer (for example, a tautomer) of the above formula Esters and ether derivatives (for example, benzoate, caprylic acid, palmitate) which can be formed during the preparation are also included in the components referred to in the present invention.
  • Curcumin may be chemically synthesized.
  • the above extract or its component is used as an active ingredient of a skin external composition in the field of cosmetics or dermatology, generally 0.001 to 10% by weight as a dry weight, based on the total weight of the composition. It is preferably formulated as 0.001 to 5% by weight. If the amount is less than 0.001% by weight, the effects of the present invention are not sufficiently exerted. On the other hand, if the amount exceeds 10% by weight, no significant improvement in the effect is observed, and formulation is difficult. Is not preferred.
  • the composition thus formulated may be pure water or ion-exchanged water or buffered water as a diluent or carrier, or a lower alcohol such as methanol, ethanol or isopropyl alcohol.
  • composition of the present invention further includes other components usually used in external preparations such as cosmetics and pharmaceuticals, such as a whitening agent, a humectant, an antioxidant, and an oily component, as long as the effects of the present invention are not impaired.
  • cosmetics and pharmaceuticals such as a whitening agent, a humectant, an antioxidant, and an oily component, as long as the effects of the present invention are not impaired.
  • An ultraviolet absorber, a surfactant, a thickener, a higher alcohol, a powder component, a coloring agent, an aqueous component, water, various skin nutritional agents, and the like can be appropriately compounded as required.
  • composition of the present invention includes sequestering agents such as sodium edetate, trisodium edetate, sodium citrate, sodium polyphosphate, sodium metalate, gluconic acid, caffeine, tannin, verapamil. , Tranexamic acid and its derivatives, licorice extract, Gravlidine, hot water extract of carin fruits, other crude drugs, drugs such as tocopherol acetate, glycyrrhizic acid and its derivatives or salts thereof, bismuth mine (: magnesium ascorbate, glucoscorbate) Appropriate blending of whitening agents such as side, arbutin and kojic acid, sugars such as glucose, fructose, mannose, sucrose and trehalose, and vitamin A derivatives such as retinoic acid, retinol, retinol acetic acid and retinol palmitic acid May be.
  • sequestering agents such as sodium edetate, trisodium edetate, sodium
  • composition of the present invention is not particularly limited in its dosage form, and may be a solution system, a solubilizing system, an emulsifying system, a powder dispersion system, a water-oil-two-layer system, a water-oil-one powder three-layer system, an ointment. It can be in any dosage form, such as gels, aerosols and the like. In addition, the form of use may be arbitrary. For example, in addition to facial cosmetics and foundations such as lotions, emulsions, creams, packs, etc., makeup cosmetics for hair, cosmetics for hair, aromatic cosmetics, Bath agents and the like can be used, but are not limited to these examples.
  • an extract derived from a medicinal plant or a component thereof is transdermally administered to the subject's skin or the entire body skin as the above composition.
  • the dosage is not limited because the optimal amount varies depending on the age, sex, and skin condition of the subject, but the composition prepared as described above is usually administered to the skin once or several times a day. do it.
  • Extract of Ibukijakosozochi or Tachijiakosozozo 50 g of whole plant of Ibukijakozodoko was soaked in ethanol for 1 week at room temperature, and the extract was concentrated to obtain 1.5 g of ethanol extract.
  • the above operation was performed using the whole plant of Tachijiakosoji instead of the whole plant of Ibukijiakosozo to obtain an ethanol extract of Tachijiakososo.
  • Each plant was obtained from a supplier (for example, Nichimen Co., Ltd.) and prepared in the same manner as the above-mentioned extract of Ibukiziya Koso.
  • MMP-1 is described as an enzyme belonging to the collagenase group
  • MMP-9 as an enzyme belonging to the gelatinase group
  • MMP-3 as an enzyme belonging to the stromelysin group. (All were made by Gagay).
  • the subjects were 100 healthy women randomly selected from the age of 25 to 60, and applied each cosmetic for one full month every day so that the preparation would spread evenly on the facial skin.
  • the improvement effect on glue and sag was examined. Table 2 shows the results.
  • oil phase Maintained at 70 ° C (oil phase).
  • the oil phase was gradually added to the aqueous phase, and after the addition was completed, the temperature was maintained for a while to cause a reaction. Then, the homomixer The mixture was uniformly emulsified and cooled to 30 ° C with good stirring to obtain a cream.
  • a cream was prepared in the same manner as in Example 1 except that 0.001% by weight of curcumin was replaced with 0.001% by weight of konkon extract (a commercially available product manufactured by Maruzen Pharmaceutical Co., Ltd.). Obtained.
  • a cream was obtained in the same manner as in Example 1 except that 0.001% by weight of curcumin was replaced by 0.001% by weight of water.
  • phase A Dissolve the carboxyvinyl polymer in a small amount of ion-exchanged water (phase A) c
  • phase A ion-exchanged water
  • phase A ion-exchanged water
  • c Add polyethylene glycol 1500 and triethanolamine to the remaining ion-exchanged water, dissolve by heating and maintain at 70 ° C (aqueous phase). Mix the other ingredients, heat and melt, and keep at 70 ° C (oil phase).
  • oil phase to water phase pre-emulsify, add phase A, homogenize uniformly with homomixer, and after emulsification, cool to 30 ° C with good stirring.
  • phase A Dissolve phase A, phase B, and phase C uniformly, and add phase B to phase A for solubilization. Next, this is added to the C phase and then filled.
  • Example 12 Emulsion type foundation (cream type)
  • aqueous phase After heating and agitating the aqueous phase, add a powder portion that has been sufficiently mixed and pulverized, and treat with a homomixer. Further, the oil phase mixed by heating is added, and the mixture is subjected to a homomixer treatment. Then, a flavor is added with stirring, and the mixture is cooled to room temperature.
  • phase A (13) (phase A). Meanwhile, the rest (13) (6) and (7) were added to the mixture, and the mixture was dissolved by heating and kept at 70 ° C (aqueous phase).
  • (1) to (5) and (9) to (12) were mixed, heated and melted, and kept at 70 ° C (oil phase).
  • the oil phase was added to the water phase, pre-emulsification was performed, phase A was added, and the mixture was uniformly emulsified with a homomixer. After the emulsification, the mixture was cooled to 30 ° C while stirring well to obtain an emulsion.
  • (1) to (7) and (9) to (12) are mixed, heated and melted, and kept at 70 ° C. (Oil phase). While stirring the oil phase, the aqueous phase was gradually added thereto, and the mixture was uniformly emulsified with a homomixer. After emulsification, the mixture was cooled to 30 ° C while stirring well to obtain an emulsion.
  • Ethyl alcohol (95%) 10.0 Polyoxyethylene (20 moles) Octyldodecanol 1.0 Non-tenthylene chloride 0.1 Pico extract (extracted with methanol) 1.5 Methyl paraben 0.15 (B phase)
  • phase A was added to the phase C to solubilize it. Then, after adding the phase B, the mixture was filled into a container to obtain a serum.
  • Curcumin 0.01 Olive oil 5.0 Tocoprol acetate 0.2 Ethylparaben 0.2 Flavor 0.2 (C phase)
  • Phases A, B and C were each dissolved uniformly, and phase B was added to phase A for solubilization. Next, this was added to the phase C and filled in a container to obtain a pack.
  • Example 20 Solid foundation
  • Example 21 Emulsion type foundation (cream type)
  • a powder portion sufficiently mixed and pulverized was added and treated with a homomixer. Further, the oil phase mixed by heating was added thereto, and the mixture was subjected to a homomixer treatment. Then, a fragrance was added while stirring, and the mixture was cooled to room temperature to obtain an emulsion type emulsion.
  • Kanokoso aleriana fauriei Briquet et Zuccarini (Rosaceae)) Buttons (Paeonia suf truticosa Andrews (Poeonia montan Sims) (Pae oniaceae)), Kouchiya (Thea sinensis Linne var.
  • the maritox metallopeptase inhibitor of the present invention inhibits the activity of excellent MMP-9, MMP-1 and MMP-3, and inhibits extracellular skin by MMPs.
  • MMP-9 excellent MMP-9
  • MMP-1 excellent MMP-1
  • MMP-3 inhibits extracellular skin by MMPs.
  • the present invention can be used in the cosmetic and dermatological fields.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Birds (AREA)
  • Toxicology (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne l'utilisation, dans des cosmétiques ou dans des préparations dermatologiques, d'une substance constituée d'un extrait cru d'origine médicamenteuse, ou d'un composant de celui-ci, et possédant une activité inhibitrice des métalloprotéases matricielles de la peau humaine. En inhibant l'activité de ces métalloprotéases dans la peau, on peut protéger celle-ci du vieillissement.
PCT/JP2000/001260 1999-03-03 2000-03-03 Inhibiteur des metalloproteases matricielles et utilisation associee WO2000051562A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP05494999A JP3632951B2 (ja) 1999-03-03 1999-03-03 マトリックスメタロプロテアーゼ阻害剤
JP11/54949 1999-03-03
JP11/320747 1999-11-11
JP32074799A JP2001139466A (ja) 1999-11-11 1999-11-11 マトリックスメタロプロテアーゼ活性阻害剤および抗老化用化粧料
JP2000005704A JP2001192316A (ja) 2000-01-06 2000-01-06 マトリックスメタロプロテアーゼ阻害剤
JP2000/5704 2000-01-06

Publications (1)

Publication Number Publication Date
WO2000051562A1 true WO2000051562A1 (fr) 2000-09-08

Family

ID=27295443

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2000/001260 WO2000051562A1 (fr) 1999-03-03 2000-03-03 Inhibiteur des metalloproteases matricielles et utilisation associee

Country Status (1)

Country Link
WO (1) WO2000051562A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1284134A4 (fr) * 2000-05-26 2005-04-20 Shiseido Co Ltd Preparations pour la peau a usage externe permettant de supprimer la secretion de sebum
JP2012025777A (ja) * 2011-10-24 2012-02-09 Maruzen Pharmaceut Co Ltd 血管新生抑制剤及び外用剤
EP2889027A3 (fr) * 2008-03-31 2016-01-06 Shiseido Co., Ltd. Préparation orale, préparation d'injection, préparation externe pour la peau et procédé cosmétique pour prévenir ou améliorer les rides

Citations (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0431755A1 (fr) * 1989-11-10 1991-06-12 Unilever Plc Composition cosmétique
JPH03170407A (ja) * 1989-11-28 1991-07-24 Pacific Chem Ind Co 細胞保護剤
JPH0597655A (ja) * 1990-12-21 1993-04-20 Sanofi Sa 植物抽出物含有化粧用組成物
JPH06128133A (ja) * 1992-10-20 1994-05-10 Kobe Steel Ltd 紫外線障害防御外用剤
JPH06345636A (ja) * 1993-06-08 1994-12-20 Nonogawa Shoji Kk 化粧料
JPH07206669A (ja) * 1994-01-14 1995-08-08 Nikken Food Kk チロシナーゼ阻害活性剤
JPH07309740A (ja) * 1993-12-30 1995-11-28 L'oreal Sa 皮膚の表層と深層とに同時に作用する対老化組成物およびその用途並びに老化処置の方法
JPH0826960A (ja) * 1994-07-11 1996-01-30 Tsuneo Nanba 化粧料
JPH0867617A (ja) * 1994-08-31 1996-03-12 Tsuneo Nanba 化粧料
JPH0867615A (ja) * 1994-08-31 1996-03-12 Tsuneo Nanba 化粧料
JPH08231368A (ja) * 1995-03-01 1996-09-10 Pola Chem Ind Inc 光老化防止剤及びこれを含有する皮膚化粧料
JPH0912441A (ja) * 1995-06-27 1997-01-14 Mikimoto Pharmaceut Co Ltd 化粧料
WO1997025969A1 (fr) * 1996-01-19 1997-07-24 The University Of Michigan Procede d'inhibition du photoviellissement de la peau
JPH107580A (ja) * 1996-06-15 1998-01-13 Michio Yoshida コラゲナ−ゼ阻害剤
US5747538A (en) * 1994-03-18 1998-05-05 L.V.M.H. Recherche Use of ginsenoside R0 or a plant extract containing same to promote collagen synthesis
US5780060A (en) * 1994-02-02 1998-07-14 Centre National De La Recherche Scientifique Microcapsules with a wall of crosslinked plant polyphenols and compositions containing them
JPH10194982A (ja) * 1997-01-14 1998-07-28 Noevir Co Ltd コラゲナーゼ阻害剤及びこれを含有する皮膚の老化防止用外用剤
US5824320A (en) * 1994-11-25 1998-10-20 Laboratories De Biologie Vegetale Yves Rocher Cosmetic or pharmaceutical compositions containing, as active ingredient, mangiferine or its derivatives, in pure form or in plant extracts
JPH10291929A (ja) * 1997-04-21 1998-11-04 Nagase & Co Ltd シワ形成抑制皮膚外用剤
JPH1171294A (ja) * 1997-08-29 1999-03-16 Pias Arise Kk コラゲナーゼ阻害剤
JPH1179971A (ja) * 1997-09-03 1999-03-23 Shiseido Co Ltd 抗老化剤
JPH1179970A (ja) * 1997-09-03 1999-03-23 Shiseido Co Ltd コラゲナーゼ阻害剤
JPH11315008A (ja) * 1998-03-03 1999-11-16 Shiseido Co Ltd 抗老化剤
JPH11349436A (ja) * 1998-06-03 1999-12-21 Noevir Co Ltd コラゲナーゼ阻害剤及びこれを含有する皮膚外用剤
JP2000026228A (ja) * 1998-07-10 2000-01-25 Nippon Flour Mills Co Ltd コラゲナーゼ抑制剤、保湿剤並びにそれらを含む化粧料及び食品

Patent Citations (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0431755A1 (fr) * 1989-11-10 1991-06-12 Unilever Plc Composition cosmétique
JPH03170407A (ja) * 1989-11-28 1991-07-24 Pacific Chem Ind Co 細胞保護剤
JPH0597655A (ja) * 1990-12-21 1993-04-20 Sanofi Sa 植物抽出物含有化粧用組成物
JPH06128133A (ja) * 1992-10-20 1994-05-10 Kobe Steel Ltd 紫外線障害防御外用剤
JPH06345636A (ja) * 1993-06-08 1994-12-20 Nonogawa Shoji Kk 化粧料
JPH07309740A (ja) * 1993-12-30 1995-11-28 L'oreal Sa 皮膚の表層と深層とに同時に作用する対老化組成物およびその用途並びに老化処置の方法
JPH07206669A (ja) * 1994-01-14 1995-08-08 Nikken Food Kk チロシナーゼ阻害活性剤
US5780060A (en) * 1994-02-02 1998-07-14 Centre National De La Recherche Scientifique Microcapsules with a wall of crosslinked plant polyphenols and compositions containing them
US5747538A (en) * 1994-03-18 1998-05-05 L.V.M.H. Recherche Use of ginsenoside R0 or a plant extract containing same to promote collagen synthesis
JPH0826960A (ja) * 1994-07-11 1996-01-30 Tsuneo Nanba 化粧料
JPH0867617A (ja) * 1994-08-31 1996-03-12 Tsuneo Nanba 化粧料
JPH0867615A (ja) * 1994-08-31 1996-03-12 Tsuneo Nanba 化粧料
US5824320A (en) * 1994-11-25 1998-10-20 Laboratories De Biologie Vegetale Yves Rocher Cosmetic or pharmaceutical compositions containing, as active ingredient, mangiferine or its derivatives, in pure form or in plant extracts
JPH08231368A (ja) * 1995-03-01 1996-09-10 Pola Chem Ind Inc 光老化防止剤及びこれを含有する皮膚化粧料
JPH0912441A (ja) * 1995-06-27 1997-01-14 Mikimoto Pharmaceut Co Ltd 化粧料
WO1997025969A1 (fr) * 1996-01-19 1997-07-24 The University Of Michigan Procede d'inhibition du photoviellissement de la peau
JPH107580A (ja) * 1996-06-15 1998-01-13 Michio Yoshida コラゲナ−ゼ阻害剤
JPH10194982A (ja) * 1997-01-14 1998-07-28 Noevir Co Ltd コラゲナーゼ阻害剤及びこれを含有する皮膚の老化防止用外用剤
JPH10291929A (ja) * 1997-04-21 1998-11-04 Nagase & Co Ltd シワ形成抑制皮膚外用剤
JPH1171294A (ja) * 1997-08-29 1999-03-16 Pias Arise Kk コラゲナーゼ阻害剤
JPH1179971A (ja) * 1997-09-03 1999-03-23 Shiseido Co Ltd 抗老化剤
JPH1179970A (ja) * 1997-09-03 1999-03-23 Shiseido Co Ltd コラゲナーゼ阻害剤
JPH11315008A (ja) * 1998-03-03 1999-11-16 Shiseido Co Ltd 抗老化剤
JPH11349436A (ja) * 1998-06-03 1999-12-21 Noevir Co Ltd コラゲナーゼ阻害剤及びこれを含有する皮膚外用剤
JP2000026228A (ja) * 1998-07-10 2000-01-25 Nippon Flour Mills Co Ltd コラゲナーゼ抑制剤、保湿剤並びにそれらを含む化粧料及び食品

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1284134A4 (fr) * 2000-05-26 2005-04-20 Shiseido Co Ltd Preparations pour la peau a usage externe permettant de supprimer la secretion de sebum
EP2889027A3 (fr) * 2008-03-31 2016-01-06 Shiseido Co., Ltd. Préparation orale, préparation d'injection, préparation externe pour la peau et procédé cosmétique pour prévenir ou améliorer les rides
JP2012025777A (ja) * 2011-10-24 2012-02-09 Maruzen Pharmaceut Co Ltd 血管新生抑制剤及び外用剤

Similar Documents

Publication Publication Date Title
WO2001089471A2 (fr) Preparations pour la peau a usage externe permettant de supprimer la secretion de sebum
JP2003201229A (ja) マトリックスメタロプロテアーゼ活性阻害剤および抗老化用化粧料
JP2003081749A (ja) 皮膚外用剤
JP2006241148A (ja) コラゲナーゼ阻害剤及び老化防止用皮膚外用剤
JP2003201214A (ja) マトリックスメタロプロテアーゼ活性阻害剤
JPH11315008A (ja) 抗老化剤
JP2001139466A (ja) マトリックスメタロプロテアーゼ活性阻害剤および抗老化用化粧料
JPH1029927A (ja) 抗老化剤
JPH1029924A (ja) 抗老化剤
TW586938B (en) Cosmetic composition of Uncaria gambir Roxburgh for antiaging
JPH1017460A (ja) 抗老化剤
JPH11246338A (ja) 抗老化剤
JPH11246337A (ja) 抗老化剤
JP2008255043A (ja) 皮膚外用剤
JP2000226311A (ja) 抗老化剤
WO2000051562A1 (fr) Inhibiteur des metalloproteases matricielles et utilisation associee
JPH07258063A (ja) 皮膚外用剤
JP4653513B2 (ja) 皮膚外用剤
JPH11246387A (ja) 抗老化剤
JP2000256122A (ja) マトリックスメタロプロテアーゼ阻害剤
JPH11246385A (ja) 抗老化剤
JP3686394B2 (ja) 抗老化剤、メイラード反応阻害剤、コラゲナーゼ活性阻害剤及びこれらを含有する皮膚老化防止用化粧料
JP2004315492A (ja) 抗老化化粧料
JPH11246386A (ja) エラスターゼ阻害剤
JP4368072B2 (ja) 皮膚外用剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CN KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): DE FR GB IT

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase